Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out
May 24, 2017 at 15:34 PM EDT
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.